Search

Displaying results 4051 - 4060 of 4235 in total
  1. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

  2. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of ...

  3. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.

  4. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...

  5. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  6. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  7. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

  8. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    [A262097] For the small-molecule approach, most earlier generations of VEGFR inhibitors such as [sunitinib], [sorafenib], [regorafenib], and [pazopanib] have poor selectivity, thus increasing the risk

  9. Drug

    1-Testosterone

    go.drugbank.com/drugs/DB01481
    IllicitInvestigational

    1-Testosterone is an anabolic steroid that differs from testosterone by having a 1,2-double bond instead of 4,5-double bond in its A ring.

  10. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).